Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance

References

• Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–634.
   PubMed Web of Science ®Google Scholar
• Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465–473.
   PubMed Web of Science ®Google Scholar
• Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125::490–493.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Suárez-Gea ML, Lecumberri R, et al. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag. 2013;9:207–228.
   PubMedGoogle Scholar
• Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49:1404–1413.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Eckert L, Wang Y, et al. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013;18:1321–1329.
   PubMed Web of Science ®Google Scholar
• Cohoon KP, Ransom JE, Leibson CL, et al. Direct medical costs attributable to cancer-associated venous thromboembolism: a population-based longitudinal study. Am J Med. 2016;129:1000.e15–25.
   PubMed Web of Science ®Google Scholar
• Carrier M, Khorana AA, Zwicker JI, et al. subcommittee on haemostasis and malignancy for the SSC of the ISTH. venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost. 2012;10:2599–2601.
   PubMedGoogle Scholar
• Prandoni P, Aw L, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW. Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res. 2018;S0049–S3848(18):30044–30046.
   Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153.
   PubMed Web of Science ®Google Scholar
• Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677–686.
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119:1062–1072.
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729–1735.
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12:389–396.
   PubMed Web of Science ®Google Scholar
• Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001;33:77–90.
   PubMed Web of Science ®Google Scholar
• Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009;37:349–356.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.
   PubMed Web of Science ®Google Scholar
• National comprehensive cancer network clinical practice guidelines in oncology: cancer associated venous thromboembolic disease – version 1. 2018 https://www.nccn.org [cited 2018 May 28].
   Google Scholar
• Mandalà M, Labianca R. European society for medical oncology. venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. Thromb Res. 2010;125:S117–S9.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest. 2016;149:315–352.
   PubMed Web of Science ®Google Scholar
• Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–e66.
   PubMed Web of Science ®Google Scholar
• Hg W, Keeling D, Laffan M, et al. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170:640–648.
   PubMed Web of Science ®Google Scholar
• Siragusa S, Armani U, Carpenedo M, et al. Italian society for haemostasis and thrombosis. prevention of venous thromboembolism in patients with cancer: guidelines of the italian society for haemostasis and thrombosis (SISET). Thromb Res. 2012;129(5):e171–e6.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Yannicelli D, McCrae KR, et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51–53.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Springmann V, Schulman S, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting: the recovery study. Thromb Haemost. 2012;108:493–498.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec;13(12):2187–2191.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Segers A, et al. Hokusai-VTE investigators. edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3(8):e379–e87.
   PubMed Web of Science ®Google Scholar
• Mh P, Aw L, Ta B, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37–e46.
   PubMed Web of Science ®Google Scholar
• Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114(1):150–157.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e120S–e151S.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Prandoni P. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med. 2015;10:651–656.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van EsN, Verhamme P, et al. Hokusai VTE cancer investigators. edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 May;10:JCO2018788034. Epub ahead of print.
   Google Scholar
• Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014 Dec;134(6):1214–1219. Epub 2014 Oct 8.
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2008;123:837–844.
   PubMed Web of Science ®Google Scholar
• Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011;(6):CD006650. DOI:10.1002/14651858.CD006650.pub3
   PubMed Web of Science ®Google Scholar
• Posch F, Königsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136:582–589.
   PubMed Web of Science ®Google Scholar
• Brunetti ND, Gesuete E, De Gennaro L, et al. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study. Int J Cardiol. 2017;230:214–221. Epub 2016 Dec 27.
   PubMed Web of Science ®Google Scholar
• Imberti D, Agnelli G, Ageno W, et al. MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica. 2008;93(2):273–278.
   PubMed Web of Science ®Google Scholar
• Spirk D, Ugi J, Korte W, et al. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. the Swiss Venous Thromboembolism Registry (SWIVTER) II. Thromb Haemost. 2011;105(6):962–967.
   PubMed Web of Science ®Google Scholar
• Matzdorff A, Ledig B, Stuecker M, et al. Practice patterns for prophylaxis and treatment of venous thromboembolism in German cancer patients. Oncol Res Treat. 2016;39:194–201.
   PubMed Web of Science ®Google Scholar
• Gussoni G, Frasson S, La Regina M, et al. RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131(1):24–30.
   PubMed Web of Science ®Google Scholar
• Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19(1):82–93.
   PubMed Web of Science ®Google Scholar
• Wittkowsky AK. Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost. 2006;4:2090–2091.
   PubMed Web of Science ®Google Scholar
• Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 1998;158(18):2001–2003.
   PubMedGoogle Scholar
• Noble S, Prout H, Nelson A. Patients’ experiences of living with Cancer associated thrombosis: the PELICAN study. Patient Prefer Adherence. 2015;9:337.
   PubMed Web of Science ®Google Scholar
• Das S, Cohen A, Edmondson R, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996;20(5):521–527.
   PubMed Web of Science ®Google Scholar
• Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence. 2014;8:453–461.
   PubMed Web of Science ®Google Scholar
• Smrke A, Gross PL. Cancer-Associated venous thromboembolism: a practical review beyond low-molecular-weight heparins. Front Med (Lausanne). 2017;4:142.
   PubMed Web of Science ®Google Scholar
• Hulle T, Exter P, Kooiman J, et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Germini F, Agnelli G, et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest J. 2015;147(2):475–483.
   PubMed Web of Science ®Google Scholar
• Ageno W, Mantovani LG, Haas S, et al. Subgroup analysis of patients with cancer in XALIA: a noninterventional study of rivaroxaban versus standard anticoagulation for VTE. TH Open. 2017;1:e33–e42.
   PubMedGoogle Scholar
• https://ClinicalTrials.gov [cited 2018 Feb 13].
   Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. ESC scientific document group. the 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr 21;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar